Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

To evaluate the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta-analysis was conducted. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched from 1950 to October 2013....

Full description

Saved in:

Bibliographic Details
Main Authors:	Feng Sun, Sanbao Chai, Lishi Li, Kai Yu, Zhirong Yang, Shanshan Wu, Yuan Zhang, Linong Ji, Siyan Zhan
Format:	Article
Language:	English
Published:	Wiley 2015-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2015/157201
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
by: Noritaka Sawada, et al.
Published: (2020-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Perioperative glucagon-like peptide-1 receptor agonists–induced gastroparesis – Is gastric ultrasound the answer?
by: Suryakumar Narayanasamy, et al.
Published: (2024-09-01)

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
by: Ortal Resnick, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024-01-01)

Glucagon-Like Peptide-2: New Insights-New Questions
by: Gordon R Greenberg
Published: (2001-01-01)

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
by: XingChun Wang, et al.
Published: (2015-01-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01)

Salivary Hormones Leptin, Ghrelin, Glucagon, and Glucagon-Like Peptide 1 and Their Relation to Sweet Taste Perception in Diabetic Patients
by: Nada K. Al-Ghurayr, et al.
Published: (2023-01-01)

Do Lactation-Induced Changes in Ghrelin, Glucagon-Like Peptide-1, and Peptide YY Influence Appetite and Body Weight Regulation during the First Postpartum Year?
by: D. Enette Larson-Meyer, et al.
Published: (2016-01-01)

Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Lu Ding, et al.
Published: (2020-01-01)

Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing
by: Marie Kjaer, et al.
Published: (2020-01-01)

G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells
by: Jason M. Conley, et al.
Published: (2024-12-01)

Comparison Of Glucagon Like Peptide/1 Levels In Diabetic Women With Ovarian Polycystic Syndrome And Healthy Women
by: Namra Iqtidar, et al.
Published: (2024-09-01)

Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
by: Alessandra Puddu, et al.
Published: (2013-01-01)

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes
by: Alessandra Puddu, et al.
Published: (2013-01-01)

β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion
by: WANG Wei, et al.
Published: (2025-01-01)

A New Way for Beta Cell Neogenesis: Transdifferentiation from Alpha Cells Induced by Glucagon-Like Peptide 1
by: Zhen Zhang, et al.
Published: (2019-01-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
by: Kazuo Kobayashi, et al.
Published: (2021-01-01)

3-(5-Hydroxyphenyl)-5-Phenyl-2-Pyrazolines as Toll-Like Receptor 7 Agonists
by: Ji Hwan Kim, et al.
Published: (2023-01-01)

Biological mechanisms of dopamine D2-like receptor agonist therapy in diabetes
by: Zachary Freyberg, et al.
Published: (2025-01-01)

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
by: P. B. Jeppesen, et al.
Published: (2009-01-01)

A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients
by: David L Sigalet, et al.
Published: (2013-01-01)

Polymorphisms in the Glucagon-Like Peptide 1 Receptor (GLP-1R) Gene Are Associated with the Risk of Coronary Artery Disease in Chinese Han Patients with Type 2 Diabetes Mellitus: A Case-Control Study
by: Xiaowei Ma, et al.
Published: (2018-01-01)

Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists
by: Fabiana Evaristo-Mendonça, et al.
Published: (2019-01-01)

Antiflammin-2 Activates the Human Formyl-Peptide Receptor Like 1
by: Ahmad M. Kamal, et al.
Published: (2006-01-01)

A TRPM4 Inhibitor 9-Phenanthrol Inhibits Glucose- and Glucagon-Like Peptide 1-Induced Insulin Secretion from Rat Islets of Langerhans
by: Zuheng Ma, et al.
Published: (2017-01-01)

To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations
by: Holli-Joi Sullivan, et al.
Published: (2020-01-01)

Serum Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) in association with the Risk of Gestational Diabetes: A Prospective Case-Control Study
by: Maryam Mosavat, et al.
Published: (2020-01-01)

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function
by: P. B. Jeppesen, et al.
Published: (2009-01-01)